Drugs Made In America Acquisition II Corp. Reports $4.4M Net Income in Q2 2026

Drugs Made In America Acquisition II Corp. reported a net income of $4.4 million for the second quarter of 2026, a significant turnaround from a net loss of $38,073 in the same period of the previous year. For the first half of 2026, the company achieved a net income of $8.7 million, compared to a loss of $97,400 in the first half of 2025. The positive financial performance was primarily driven by interest income of $4.5 million for the quarter and $8.9 million for the six months, generated from cash and investments held in a trust account, which totaled approximately $513.9 million as of June 30, 2026.

The company’s operating expenses increased to $112,227 for the second quarter of 2026, up from $38,073 in the same quarter of 2025. For the first half of 2026, operating expenses reached $244,257, compared to $97,400 in the prior year. The increase in expenses is attributed to higher general and administrative costs as the company prepares for its initial business combination, which remains its primary focus. As of June 30, 2026, the company had a working capital deficit of $426,751, reflecting its ongoing operational costs.

Drugs Made In America Acquisition II Corp. has not yet identified a target for its initial business combination, which it aims to complete within 24 months from the closing of its Initial Public Offering (IPO) in September 2025. The IPO raised $500 million, with an additional $12 million from a private placement. The company has incurred transaction costs of approximately $28.4 million related to the IPO, including underwriting fees and other offering costs. The funds from the IPO are held in a trust account, which will be utilized for the business combination or returned to shareholders if the combination is not completed within the specified timeframe.

As of June 30, 2026, the company had 13.7 million ordinary shares outstanding, excluding 50 million shares subject to possible redemption. The company’s management has expressed concerns regarding its ability to continue as a going concern, citing the need to complete a business combination within the designated period to avoid liquidation. The filing indicates that the company is subject to various risks, including market volatility and geopolitical uncertainties, which could impact its ability to finalize a business combination successfully.

Looking ahead, Drugs Made In America Acquisition II Corp. remains focused on identifying a suitable target in the pharmaceutical industry, leveraging its substantial cash reserves. However, the company acknowledges the challenges it faces in executing its business strategy, particularly in light of the current economic environment and the need for effective operational management. The management team continues to evaluate potential acquisition opportunities while managing costs and ensuring compliance with regulatory requirements.